Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
206 results about "Ferroptosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Ferroptosis is a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides, and is genetically and biochemically distinct from other forms of regulated cell death such as apoptosis. Ferroptosis is initiated by the failure of the glutathione-dependent antioxidant defenses, resulting in unchecked lipid peroxidation and eventual cell death. Lipophilic antioxidants and iron chelators can prevent ferroptotic cell death.
Quinazolinone-based oncogenic-ras-selective lethal compounds and their use
The present invention provides, inter alia, compounds having the structure (1) compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Ternary complex nanometer system and preparation method and application thereof
ActiveCN109806252AGood photothermal effectEnhance killing activityOrganic active ingredientsPharmaceutical non-active ingredientsFenton reactionTernary complex
The invention discloses a ternary complex nanometer system and a preparation method and application thereof. The system comprises an iron compound, a benzene-ring-containing micromolecule antineoplastic active compound and a polyphenol compound; a weight ratio of the iron compound to the benzene-ring-containing micromolecule antineoplastic active compound to the polyphenol compound is (1 to 4):(2to 10):(5 to 20). Relative to the prior art, according to the invention, different micromolecule compounds or medicines can be stably assembled only by a physical assembling means; the formed complexnanometer medicine not only has an antineoplastic treatment effect of the micromolecule antineoplastic active compound, but also has a ferroptosis treatment effect that the iron compound reacts with the polyphenol compound are mediated on the basis of an intracellular Fenton reaction; moreover, the novel complex nanometer medicine formed by the preparation method disclosed by the invention furtherhas an outstanding photothermal effect; chemotherapy, ferroptosis treatment and photothermal therapy can be integrated into one whole body, take a synergistic effect, beneficiate each other and achieve an all-in-one combined antineoplastic treatment effect.
Owner:CHINA PHARM UNIV
Application of ferroptosis inhibitor in preparation of medicine for treating acute liver injury
InactiveCN111265510ALower AST levelsLower levelOrganic active ingredientsDigestive systemInflammatory cellHepatocyte
The invention discloses an application of a ferroptosis inhibitor in preparation of a medicine for treating an acute liver injury. A ferroptosis inhibitor is pretreated to remarkably reduce levels ofglutamic-pyruvic transaminase ALT and glutamic oxalacetic transaminase AST in serum after the acute liver injury induced by sodium thiosulfate TAA; an MDA content in liver tissues after the TAA-induced acute liver injury is reduced, and the contents of reduced glutathione GSH and glutathione peroxidase GSH-PX in the liver tissues are increased; infiltration of inflammatory cells in the TAA-inducedacute liver injury to a liver is reduced; and a protective effect of the ferroptosis inhibitor on the TAA-induced acute liver injury is related to inhibition of hepatocyte ferroptosis, and ferroptosis marker gene glutamic acid/cystine reverse transporter xCT and Gpx4 glutathione peroxidase 4 in a TAA-induced acute liver injury model can be remarkably improved by the ferroptosis inhibitor.
Owner:NANTONG UNIVERSITY
Preparation and uses of reactive oxygen species scavenger derivatives
Compounds of Formula (I)a or (I)b:including certain quinone derivatives, and the corresponding pharmaceutical compositions, which may serve to modulate ferroptosis in a subject. Also disclosed herein are the preparations of these compounds and pharmaceutical compositions and their potential uses in the manufacture of a medicament in reducing reactive oxygen species (ROS) in a cell and for preventing, treating, ameliorating certain related disorder or a disease.
Owner:XWPHARMA LTD
Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
The present invention provides, inter alia, compounds having the structure (1) compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Pyrite nano-enzyme, antitumor drug and application
ActiveCN112791099AHigh intensity peroxidase (POD) activityValence does not changeHeavy metal active ingredientsNanomedicinePeroxidaseApoptosis
The invention provides a pyrite nano-enzyme, an antitumor drug and application. The pyrite nano-enzyme comprises Fe < 2 + > and S 2< 2->, the atomic ratio of Fe to S is 1: 2, and the pyrite nano-enzyme presents a FeS2 crystal form. The pyrite nano enzyme has peroxidase activity (POD) and glutathione oxidase activity (GSH-OXD) at the same time; the catalytic efficiency (kcat / KM) of converting H2O2 into. OH under the active catalysis of POD is (8.5-9.5) * 10 < 8 > s <-1 > M <-1 >, and the catalytic efficiency (kcat / KM) of oxidizing GSH into GSSG and H2O2 under the active catalysis of GSH-OXD is (1-1.4) * 10 < 8 > s <-1 > M <-1 >. The POD and GSH-OXD activities of the pyrite nano-enzyme can form a cascade reaction to cause tumor cells to generate. OH and to deplete GSH in the cells, so that apoptosis and ferroptosis of the tumor cells occur; the killing effect has tumor cell specificity, and the killing effect on normal cells is very weak; the pyrite nano-enzyme has degradability, so that excellent safety is ensured; the pyrite nano-enzyme can exert POD and GSH-OXD activities in tumor cells in vivo, and can achieve an excellent treatment effect in apoptosis-resistant CT26 tumors containing KRAS mutations by inducing apoptosis and ferroptosis of tissues.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Compounds, Compositions, and Methods For Modulating Ferroptosis and Treating Excitotoxic Disorders
The present invention provides, inter alia, a compound having the structure: (Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Carbonyl erastin analogs and their use
The present invention provides, inter alia, compounds having the structure of formula (I): Compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
ROS-sensitive nano-reagent capable of synergistically inducing photodynamic therapy and ferroptosis and preparation method therefor
ActiveCN112451680AEasy to prepareSimple methodOrganic active ingredientsEnergy modified materialsPhotosensSide chain
The invention relates to a ROS-sensitive nano-reagent capable of synergistically inducing photodynamic therapy and ferroptosis and a preparation method therefor and belongs to the technical field of biomedicines. The nano-reagent is constructed from a photosensitizer-modified ROS-sensitive amphiphilic block polymer and comprises an amphiphilic biodegradable polymer and a ROS-sensitive perceptual monomer capable of inducing the ferroptosis, of which a tail end is connected with a photosensitizer group and a lateral chain is modified; and the amphiphilic polymer can self-assemble to form the ROS-sensitive nano-reagent capable of synergistically inducing the photodynamic therapy and the ferroptosis, a hydrophobic part self-assembles to form a hydrophobic core, and a hydrophilic part becomes ahydrophilic shell. Finally, the photosensitizer-modified ROS-sensitive amphiphilic block polymer is driven to self-assemble to form the ROS-sensitive nano-reagent capable of synergistically inducingthe photodynamic therapy and the ferroptosis by using a film dispersion method, and the effect of inhibiting tumor growth by a synergistic action of photodynamic and ferroptosis treatment in the presence of a tumorous microenvironment is achieved.
Owner:JILIN INST OF CHEM TECH
Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
The present invention provides, inter alia, a compound having the structure: (Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Fluorescent probe based on quinoxalinone aryl sulfides as well as preparation method and application thereof
ActiveCN108117547ARealize in situ detectionQuick checkOrganic chemistryFluorescence/phosphorescenceChemical structureIn vivo
The invention provides a fluorescent probe based on quinoxalinone aryl sulfides as well as a preparation method and application thereof. A chemical structure of a fluorescent probe molecule is shown in formula (I) (shown in the specification), wherein R is selected from allyl and derivatives thereof, benzyl and derivatives thereof, fatty acid ester groups with the carbon atom number of 1-8 or fatty acid with the carbon atom number of 1-8; R1 is selected from alkoxy with the carbon atom number of 1-8, halogen or alkyl with the carbon atom number of 1-8; and R2 is aryl sulfides. The fluorescentprobe molecule is obtained by cyclizing o-phenylenediamine and derivatives thereof, carrying out nucleophilic substitution and carrying out aldol condensation reaction. The quinoxalinone derivative compound turns red fluorescence into green fluorescene after thioether is oxidized into sulfoxide in the presence of up-regulated heme oxidase and active oxygen in ferroptosis cells. The fluorescent probe provided by the invention can be directly added into a culture medium, then acts on cells and carries out detection, and also can be directly injected intravenously or intratumorally and play a role of animal in vivo detection.
Owner:SHANGHAI JIAO TONG UNIV
Application of aucubin or aglycone thereof to preparation of medicine for inhibiting ferroptosis
InactiveCN111870613AEnrich the basis of pharmacological actionReveal inhibitoryOrganic active ingredientsNervous disorderAucubinAucuba chinensis
The invention discloses an application of aucubin or aglycone thereof to preparation of a medicine for inhibiting ferroptosis, belongs to the field of an application of traditional Chinese medicine extracts, and particularly provides an application of aucubin or aglycone thereof to preparation of the medicine for inhibiting ferroptosis. The invention relates to an application of aucubin, in particular to an application of aucubin or aglycone thereof to preparation of the medicine for preventing or treating diseases related to ferroptosis. The inhibition effect and the molecular mechanism of the aucubin or the aglycone thereof on ferroptosis are disclosed for the first time, the pharmacological action basis of the aucubin or the aglycone thereof is enriched, and a new way is provided for prevention or treatment of diseases related to ferroptosis.
Owner:PEOPLES HOSPITAL OF HENAN PROV +1
Ferroptosis model construction method and application
PendingCN113782090APredict overall survivalRealize intelligent predictionMedical data miningHealth-index calculationChemo therapyCancer research
The invention belongs to the field of artificial intelligence technology application, and particularly relates to a ferroptosis model construction method and application. The method specifically comprises the following steps: screening out a plurality of ferroptosis regulation molecules with large expression level change by adopting an existing gene expression database and ferroptosis regulation molecules, and typing the gastric cancer by adopting a consensus clustering method; performing gene expression difference analysis on the gastric cancer subtypes to obtain differential expression genes; then screening survival prognosis-related differential genes and regression coefficients thereof from the differential expression genes by adopting single-gene Cox regression analysis, and obtaining survival-related differential genes i of the patient to be analyzed; and counting the expression quantity Expi of the survival-related differential gene i, and constructing a ferroptosis model according to a regression coefficient betai corresponding to the survival-related differential gene i: ferroptosis score = [sigma]*Exp. The ferroptosis score can well predict survival prognosis, chemotherapy drug sensitivity and immunotherapy effect of the gastric cancer patient.
Owner:THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
Nano-drug for tumor ferroptosis-gas synergistic treatment and preparation method thereof
ActiveCN112843250ACause degradationAchieve ferroptosisPowder deliveryHeavy metal active ingredientsPharmacologyHydrogen peroxide
The invention discloses a nano-drug for tumor ferroptosis-gas synergistic treatment. The nano-drug comprises biodegradable hollow mesoporous organic silicon nano particles, carbonyl iron compounds loaded in the hollow mesoporous organic silicon nano particles and a small molecule drug. The invention further discloses a preparation method of the nano-drug for tumor ferroptosis-gas synergistic treatment and application of the nano-drug to preparation of tumor treatment drugs. The preparation method is simple to operate and can be used for repeated large-scale preparation. According to the nano-drug disclosed by the invention, sulfur-sulfur bonds are introduced to react with over-expressed glutathione in a tumor micro-environment, so that a hollow mesoporous organic silicon skeleton is broken, the loaded small-molecule drug is released, and the whole nano-drug is degraded; and the loaded carbonyl iron compound responds to excessive hydrogen peroxide in a tumor micro-environment, so that CO can be released, ferroptosis can be realized, and the synergistic effect of gas treatment and ferroptosis can be realized.
Owner:NINGBO INST OF MATERIALS TECH & ENG CHINESE ACADEMY OF SCI +1
Application of ferroptosis inducer RSL3, and medicine for treating liver cancer
ActiveCN113018297APrevent proliferationGood medicinal potentialOrganic active ingredientsDigestive systemOncologyPharmacology
The invention discloses an application of a ferroptosis inducer RSL3 in treatment of sorafenib drug-resistant liver cancer, and belongs to the technical field of cytobiology and medicine. Specifically, RSL3 with different concentrations is added into HepG2 and HepG2 drug-resistant cells, the cell activity is detected by using a Cell Counting Kit-8 method, and it is found that compared with the HepG2 cells, the relative activity of the HepG2 drug-resistant cells is remarkably reduced, and the RSL3 can inhibit proliferation of liver cancer drug-resistant cells. Meanwhile, compared with the accumulation condition of lipid oxides of HepG2 and HepG2 drug-resistant cells, the lipid oxides of the HepG2 drug-resistant cells are remarkably increased after the RSL3 is added, so that ferroptosis is caused. The ferroptosis inducer RSL3 has good medicinal potential in treatment of drug-resistant tumors.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
System for evaluating immunotherapy reactivity of glioblastoma patient based on ferroptosis level and analysis method
PendingCN113421613AResponsive PredictionGood effectMicrobiological testing/measurementBiostatisticsEfficacyOncology
The invention discloses a system for evaluating immunotherapy reactivity of a glioblastoma patient based on a ferroptosis level and an analysis method, and belongs to the technical field of immunotherapy reactivity analysis. The system for evaluating the immunotherapy reactivity of the glioblastoma patient based on the ferroptosis level comprises an input module, an analysis module and an output module. The system for evaluating the immunotherapy reactivity of the glioma patients based on the ferroptosis level is established by summarizing data of 1750 glioma patients from four independent databases, and by calculating and comparing the ferroptosis level, the malignant development of glioma, the length of prognosis lifetime, the anti-tumor immunity and the reactivity of immunotherapy can be predicted. Meanwhile, the system can predict whether the immunotherapy effect can be improved by inhibiting the ferroptosis level or not, and auxiliary guidance can be provided for clinical analysis and application.
Owner:吴安华
Mesoporous metal organic framework as well as preparation method and application thereof
ActiveCN111909384AResponsive to the tumor microenvironmentHigh drug loadingOrganic active ingredientsPhotodynamic therapySide effectMetal-organic framework
The invention provides a mesoporous metal organic framework as well as a preparation method and application thereof, the mesoporous metal organic framework is formed by connecting disulfide bond monomers and metal ions through non-covalent bonds, and the metal ions are Fe 2+ and Cu 2+. The mesoporous metal organic framework disclosed by the invention has the advantages of tumor microenvironment responsiveness, high drug loading capacity, low systemic side effect, good tumor local biodegradability, sufficient drug local release and low systemic side effect, and is expected to promote the further development of tumor ferroptosis and diagnosis and treatment integration.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Nanoparticles for selective death of cancer cells through ferroptosis, method of preparing the same, and use of the nanoparticles
PendingUS20200261498A1Improve stabilityEliminate side effectsHeavy metal active ingredientsPowder deliveryCancer cellTherapeutic effect
Provided are nanoparticles for the selective death of cancer cells through ferroptosis and a method of preparing the same. More particularly, the nanoparticles are in a form in which a cancer cell-targeting hydrogel and iron particles are bound and aggregated, and are selectively accumulated in cancer cells, and thus exhibit an effective cancer cell killing effect through ferroptosis, and accordingly, are expected to exhibit high therapeutic effects due to less side effects.
Owner:SEOUL NAT UNIV R&DB FOUND
Tea polyphenol-metal nanoparticles, drug-loaded nanoparticles as well as preparation method and application of tea polyphenol-metal nanoparticles and drug-loaded nanoparticles
PendingCN113577101APromote rapid formationThe preparation process is simple and environmentally friendlyHeavy metal active ingredientsSurgeryPhenolic content in teaApoptosis
The invention belongs to the field of medicines, and relates to a tea polyphenol-metal nanoparticle, a drug-loaded nanoparticle as well as a preparation method and application thereof, in particular to application of dual response of tea polyphenol through pH and glutathione to regulation of apoptosis/ferroptosis pathway in the anti-tumor research aspect. The invention provides a drug carrying system for delivering chemotherapeutic drugs, namely tea polyphenol-metal nanoparticles, aiming at cancer treatment. The tea polyphenol-metal nanoparticles are obtained by dropwise adding a metal ion storage solution into an EGCG storage solution, stirring, centrifuging and collecting precipitates; and the metal ion storage liquid and an anti-tumor drug are dropwise added into the EGCG storage liquid, the precipitate is stirred, centrifuged, and collected to obtain the drug-loaded nanoparticles. According to the medicine carrying system, the anti-tumor medicine and metal elements are simultaneously delivered to tumor tissues and are taken by tumor cells, the tea polyphenol-metal nanoparticle structure is depolymerized under the conditions of weak acidity of tumors and high-level glutathione, free metal elements are released, and the anti-tumor medicine achieves the treatment effect.
Owner:SICHUAN UNIV
Amorphous calcium carbonate composite nano-medicine with effect of inducing ferroptosis of tumor cells and preparation method of amorphous calcium carbonate composite nano-medicine
ActiveCN111228513APromotes ferroptosisFerroptosis promotionPowder deliveryHeavy metal active ingredientsDendrimerLysosome
The invention relates to an amorphous calcium carbonate composite nano-medicine with an effect of inducing ferroptosis of tumor cells and a preparation method of the amorphous calcium carbonate composite nano-medicine, and belongs to the technical field of medicines. After the composite nano-medicine enters the tumor cells, the degradation of nanoparticles is promoted by means of the acidic environment of lysosomes, meanwhile, the lysosomes are subjected to permeabilization to release doxorubicin and ferrous ions through the protonation of dendrimers, wherein ferrous ions can promote the conversion of polyunsaturated fatty acids of cell membranes to lipid peroxides and induce ferroptosis of the tumor cells, and DOX can promote oxidative stress to increase the content of hydrogen peroxide in the cells while inducing apoptosis, so that iron-dependent ferroptosis caused by lipid peroxidation induced by the ferrous irons is further enhanced. The composite nanoparticles can not only increase the therapeutic effect of tumors, but also reduce the side effects caused by chemotherapy.
Owner:CHONGQING UNIV
Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
ActiveUS20170015660A1Organic active ingredientsOrganic chemistryAbnormal tissue growthSynovial sarcoma
Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described. At least one described molecular species exhibits an IC50 value below 5 μM against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo, and led to 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Manganese-heme coordination polymer nano-particle and preparation method and application thereof
ActiveCN113456836AReduce usageHigh biosecurityEnergy modified materialsEchographic/ultrasound-imaging preparationsCoordination polymerizationApoptosis
The invention discloses a manganese-heme coordination polymer nano-particle and a preparation method and application thereof, the nano-particle is formed by manganese ions and two specific carboxyl groups in heme through coordination polymerization, the nano-particle is of a cubic structure, and the average side length is about 20 nm. The preparation method comprises the following steps: in a NaOH solution with the pH value of 7, carrying out hydrothermal synthesis reaction on a manganese source and heme at 120 DEG C for 3 hours; the nano-particle is formed by self-assembly of manganese ions and heme, due to existence of iron and manganese elements, the nano-particle can be used for 1H-MRI imaging of tumors, meanwhile, the nano-particle has excellent photo-thermal conversion performance and can be used for photo-thermal therapy and photo-acoustic imaging of the tumors. Moreover, the nano-particle has nano-enzyme catalytic activity, H2O2 can be efficiently catalyzed through Fenton reaction to generate highly toxic. OH, lipid peroxidation in cells is caused, apoptosis or necrosis of the cells is promoted through a ferroptosis pathway, and then the nano-particles can be applied to CDT and Fe death treatment of tumors.
Owner:INNOVATION ACAD FOR PRECISION MEASUREMENT SCI & TECH CAS
Methods of diagnosing and treating cancer comprising me1
The present disclosure provides a method of determining treatment for cancer comprising identifying the absence of malic enzyme 1 (ME1) and treating with an inducer of ferroptosis.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Application of Fascaplysin compound
InactiveCN113332282AIncrease iron ion concentrationOrganic active ingredientsNervous disorderPharmaceutical drugOncology
The invention discloses application of a Fascaplysin compound, and particularly relates to application of the Fascaplysin compound in preparation of a ferroptosis inducer, a medicine for improving the concentration of iron ions in cells and an anti-tumor medicine. The Fascaplysin compound can induce the occurrence of ferroptosis, regulates the death of non-small cell lung cancer cells in a novel mode of promoting cell death, can improve the concentration of the iron ions in the cells, is an effective ferroptosis inducer, and can be used for preparing and developing the anti-lung cancer medicine.
Owner:GUANGDONG ZHANJIANG PROVINCIAL LAB OF SOUTHERN MARINE SCI & ENG
Methods of enhancing radiotherapy using ferroptosis inducers as radiosensitizers
PendingUS20220193047A1Increase DNA damage and apoptosis activationImprove anti-tumor effectMicrobiological testing/measurementDisease diagnosisCancer cellRadical radiotherapy
The present disclosure provides, inter alia, methods for treating or ameliorating the effects of a cancer in a subject in need thereof by combining a radiosensitizer such as a ferroptosis inducer with radiation. Methods for identifying and treating a subject with a cancer that is resistant to radiotherapy, methods for enhancing the anti-tumor effect of radiation in a subject undergoing radiotherapy, and methods for enhancing the effect of radiation on a cancer cell are also provided.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Application of cepharanthine and salts thereof as ferroptosis inducer in preparation of anti-tumor drug
PendingCN111228269AImprove securityEffective treatment optionsOrganic active ingredientsPharmaceutical delivery mechanismProstate cancer cellAnticarcinogenic Effect
The invention relates to the technical field of medicines and provides application of cepharanthine and salts thereof as a ferroptosis inducer in preparation of an anti-tumor drug. As found, natural products, namely cepharanthine and salts thereof, which are already applied clinically for many years can induce ferroptosis of prostate cancer cells in expressive ways of active oxygen increase, accumulation of lipid peroxides, decrease in the expression level of GPX4, structural changes in mitochondria, etc. Therefore, cepharanthine and salts thereof have good anti-cancer effects and provide a new effective therapeutic drug for tumor disease patients.
Owner:GUANGZHOU JINAN BIOMEDICINE RES & DEV CENT
Ferroptosis-inducing nano-composite, preparation method and application of ferroptosis-inducing nano-composite in tumor treatment
PendingCN112933078ARich varietyHigh in ironOrganic active ingredientsHeavy metal active ingredientsArtemisininsTumor therapy
The invention discloses a ferroptosis-inducing nano-composite, a preparation method and application of the ferroptosis-inducing nano-composite in tumor treatment. The preparation method comprises the following steps of: dissolving an artemisinin medicine and an oral iron supplementing agent in an organic solvent to obtain a solution I; dispersing lactoferrin in an inorganic solvent to obtain a solution II; and adding the solution I into the solution II, and uniformly mixing under ultrasonic waves to obtain the ferroptosis-inducing nano-composite. The nano-composite prepared in the invention is loaded with the artemisinin medicine and the oral iron supplementation agent, has the characteristics of simple components and small toxic and side effects and can induce ferroptosis of tumor cells, the anti-tumor effect of the nano-composite is enhanced by regulating macrophages to be in an anti-tumor phenotype through cooperation with innate immunity, and the nano-composite can be used in the field of anti-tumor research.
Owner:GUANGXI UNIV
Method for preparing genitourinary system tumor cell ferroptosis model based on ferric ammonium citrate and application in preparation of antitumor drugs
ActiveCN111893096AIncrease concentrationPromotes ferroptosisHeavy metal active ingredientsCulture processPharmaceutical drugFerric citrate
The invention relates to a method for preparing a genitourinary system tumor cell ferroptosis model based on ferric ammonium citrate and application in preparation of antitumor drugs, and belongs to the technical field of antitumor drugs. The invention provides the method for preparing the genitourinary system tumor cell ferroptosis model based on ferric ammonium citrate. The method comprises thefollowing steps: when the density of cultured tumor cells reaches 65-75%, adding ferric ammonium citrate, and continuing to culture for 20-30 hours to obtain the ferroptosis model. The way of treatinggenitourinary system tumor cells by using the ferric ammonium citrate is a very simple, convenient and efficient method for preparing the a ferroptosis tumor cell model, and the anti-tumor activity of the ferric ammonium citrate provides a theoretical basis for subsequent research and development and clinical treatment.
Owner:刘特
Application of CDO1 in preparing stomach cancer treating drug associated with ferroptosis
InactiveCN107890567AAntineoplastic agentsPharmaceutical active ingredientsCancer deathStomach cancer
The invention belongs to the field of functions and applications of genes and proteins, and relates to the application of CDO1 in the preparation of gastric cancer treatment drugs related to ferroptosis. The invention provides a new application of CDO1, and the new application is that CDO1 is used in the preparation of gastric cancer treatment drugs related to ferroptosis. The invention provides that the agent capable of inducing ferroptosis in gastric cancer cells is Erastin. The present invention also provides that the promoter of gastric cancer cell ferroptosis process is overexpression of CDO1 plasmid. The present invention reveals for the first time the mechanism of CDO1 regulating cysteine metabolism in Erastin-induced gastric cancer cell ferroptosis and the transcriptional regulation of c-Myb on CDO1 expression during ferroptosis. CDO1 is an important part of the c-Myb signaling pathway in gastric cancer and an important metabolic node in the process of ferroptosis. Overexpression of CDO1 can promote the process of ferroptosis in gastric cancer cells. Therefore, the present invention provides a theoretical basis for the study of gastric cancer treatment based on ferroptosis, and provides an insertion point for the preparation of new gastric cancer treatment drugs.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Application of ferroptosis inhibitor Liproxstatin-1 to preparation of medicine for treating traumatic brain injury
InactiveCN111135177AReduce cerebral edemaReduce permeabilityOrganic active ingredientsNervous disorderDepressantBiomedicine
The invention discloses application of ferroptosis inhibitor Liproxstatin-1 to preparation of medicine for treating traumatic brain injury, and belongs to the technical field of biomedicines. The system of the ferroptosis inhibitor Liproxstatin-1 illustrates a time-course changing process (from 6h to 14d) of ferroptosis-related protein expression and occurrence of iron deposits after traumatic brain injury; meanwhile, the Liproxstatin-1 is dosed through an abdominal cavity after a person suffers from traumatic brain injury for 1 hour, which proves that the Liproxstatin-1 can alleviate cerebraledema and blood-brain barrier permeability caused by the traumatic brain injury; the findings proves that the Liproxstatin-1 has an improvement effect on exercise and learning memory impairment caused by the traumatic brain injury; the confirmation shows that the Liproxstatin-1 can obviously improve anxiety and cognitive functions caused by TB1; and in addition, revelation shows that a protectioneffect of the Liproxstatin-1 is related with up-regulation of FTH1 and Nrf2 and down-regulation of expression of NOX2 caused by reversion of TB1. An evidence is provided for using of the Liproxstatin-1 as a novel medicine for treating the traumatic brain injury.
Owner:SUZHOU UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap